Literature DB >> 20053162

Plasma protein binding in drug discovery and development.

Monique L Howard1, John J Hill, Gerald R Galluppi, Matthew A McLean.   

Abstract

This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited for measurement of compounds that are highly protein bound. The methods reviewed herein include the conventional techniques of equilibrium dialysis, ultrafiltration and ultracentrifugation, as well as some more novel approaches utilizing micropartitioning and biosensor-based analysis. Additional concepts that are discussed include plasma protein structure, enantioselective protein binding, drug displacement, the effect of patient demographics and disease states on free (unbound) drug levels, and the influence of protein binding on drug candidate pharmacokinetics and pharmacodynamics. Practical considerations pertaining to the evaluation of highly protein bound drug candidates are also highlighted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053162     DOI: 10.2174/138620710790596745

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  23 in total

1.  Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

Authors:  Paul K L Chin; Berit P Jensen; Helle S Larsen; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

2.  Inhibition of cell adhesion and immune responses in the mouse model of collagen-induced arthritis with a peptidomimetic that blocks CD2-CD58 interface interactions.

Authors:  Ameya S Gokhale; Rushikesh Sable; Jason D Walker; Leslie McLaughlin; Konstantin G Kousoulas; Seetharama D Jois
Journal:  Biopolymers       Date:  2015-11       Impact factor: 2.505

Review 3.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

4.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Biological barriers, and the influence of protein binding on the passage of drugs across them.

Authors:  Karolina Wanat
Journal:  Mol Biol Rep       Date:  2020-03-05       Impact factor: 2.316

7.  Humanized theta-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections.

Authors:  S Welkos; C K Cote; U Hahn; O Shastak; J Jedermann; J Bozue; G Jung; P Ruchala; P Pratikhya; T Tang; R I Lehrer; W Beyer
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

9.  Albumin-Based Transport of Nonsteroidal Anti-Inflammatory Drugs in Mammalian Blood Plasma.

Authors:  Mateusz P Czub; Katarzyna B Handing; Barat S Venkataramany; David R Cooper; Ivan G Shabalin; Wladek Minor
Journal:  J Med Chem       Date:  2020-06-17       Impact factor: 7.446

10.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.